Epsilcapramin en es it fr

Epsilcapramin Brand names, Epsilcapramin Analogs

Epsilcapramin Brand Names Mixture

  • No information avaliable

Epsilcapramin Chemical_Formula


Epsilcapramin RX_link


Epsilcapramin fda sheet

Epsilcapramin FDA

Epsilcapramin msds (material safety sheet)

Epsilcapramin MSDS

Epsilcapramin Synthesis Reference

No information avaliable

Epsilcapramin Molecular Weight

131.173 g/mol

Epsilcapramin Melting Point

205 oC

Epsilcapramin H2O Solubility

5.05E+005 mg/L

Epsilcapramin State


Epsilcapramin LogP


Epsilcapramin Dosage Forms

Solution for injection (containing 250 mg/mL of aminocaproic acid) and tablets (500, 1000mg)

Epsilcapramin Indication

For use in the treatment of excessive postoperative bleeding.

Epsilcapramin Pharmacology

Aminocaproic acid works as an antifibrinolytic. It is a derivative of the amino acid lysine. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity.

Epsilcapramin Absorption

Absorbed rapidly following oral administration. In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1).

Epsilcapramin side effects and Toxicity

A few cases of acute overdosage with intravenous administration have been reported. The effects have ranged from no reaction to transient hypotension to severe acute renal failure leading to death. The intravenous and oral LD50 were 3.0 and 12.0 g/kg respectively in the mouse and 3.2 and 16.4 g/kg respectively in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog.

Epsilcapramin Patient Information

Epsilcapramin Organisms Affected

Humans and other mammals